VivoSim Labs, Inc. VIVS
0.12 USD 0.00 (-2.83%)
As ofNov 16, 2026, 1:28 PM EST
0.1222 Day range 0.1305
0.12 52-week range 3.40
- YTD
- -93.18%
- 1 year
- -94.31%
News
benzinga.com VivoSim Labs Q2 EPS $(0.03) Up From $(0.98) YoY, Sales $51.000K Up From $28.000K YoY VivoSim Labs (NASDAQ:VIVS) reported quarterly losses of $(0.03) per share. This is a 96.94 percent increase over losses of $(0.98) per share from the same period last year. The company reported…
globenewswire.com VivoSim Labs to Showcase Multiparametric Human 3D Tissue Safety Data at the American College of Toxicology (ACT) 47th Annual Meeting SAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a leader in next-generation New Approach Methodologies (NAMs) 3d human cellular models for…benzinga.com VivoSim Labs Partners With Chemveda Life Sciences To Test, Screen AI-Derived Drug Compounds In VivoSim's NAMkind 3D Tissue Models VivoSim Labs, Inc. (Nasdaq: VIVS) ("VivoSim" or "Company"), a provider of AI-enabled New Approach Methodologies (NAMs) for preclinical safety, and Chemveda Life Sciences ("Chemveda"), an
benzinga.com VivoSim Labs To Extend Its Human Tissue Platform Beyond Toxicology With Efficacy Testing Services Built On NAMkind Disease Models Of The Liver And Intestine The disease models are built with cells from patient donors, so they carry features of the disease itself. Drug developers can measure whether a candidate acts on those disease features in human…
